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ABSTRACT
RNA interference (RNAi) is widely used for functional
studies and has been proposed as a potential thera-
peutic agent. Current RNAi systems are largely effici-
ent, but have limitations including transient effect, the
needforviralhandlingandpotentialinsertionalmuta-
tions.Here,wedescribeasimpleL1retrotransposon-
basedsystemforthedeliveryofsmallinterferingRNA
(siRNA) and stable silencing in human cells. This
system demonstrated long-term siRNA expression
and significant reduction in both exogenous and
endogenous gene expression by up to 90%. Further
characterization indicated that retrotransposition
occurred in a controlled manner such that essentially
only one RNAi-cassette was integrated into the host
genome and was sufficient for strong interference.
Our system provides a novel strategy for stable
gene silencing that is easy and efficient, and it may
have potential applications for ex vivo and in vivo
molecular therapy.
INTRODUCTION
As a potent and speciﬁc gene silencing mechanism, RNA
interference (RNAi) has revolutionized reverse genetic appro-
aches for functional studies in a variety of organisms, particu-
larly mammals (1,2). Another intriguing prospect of RNAi is
its therapeutic potential, which has been demonstrated by the
prevention of fulminant hepatitis (3,4), viral infections (5,6)
and malignancies of various tissues (7–11) in both primary
mammalian cells and animal models. RNAi involves pro-
cessing of long double-stranded RNA (dsRNA) precursors
to 21–23 nt siRNAs (12), which target the endonucleolytic
cleavage of homologous transcripts (13). Several strategies
have been developed to produce siRNA in vitro or in vivo
(1,2). For example, pol III promoter transcribed short-hairpin
RNA (shRNA) can be processed into siRNA in vivo and this
has become a commonly used strategy for speciﬁc gene silen-
cing in mammalian systems. Various vectors have been used
for shRNA delivery, including plasmid, retrovirus, adenovirus
and adeno-associated virus. Although largely efﬁcient, current
delivery vehicles have limitations, such as transient effect,
demanding viral handling and potentially causing undesirable
insertional mutations.
L1s are non-LTR retrotransposons that comprise  17% of
the human genome (14). A consensus full-length human L1 is
 6 kb, containing a 50-untranslated region (50-UTR), two
open reading frames (ORF1 and ORF2) and a 30-UTR with
poly(A) signal and a poly(A) tail. During retrotransposition,
L1 sequence is transcribed from its internal promoter located
within the 50-UTR (15) and the transcript is exported to the
cytoplasm where a ribonucleoprotein (RNP) complex is
formed with translated ORF1 (16). ORF1 has RNA-binding
activity (17) and ORF2 has endonuclease (18) and reverse
transcriptase (19) activities. L1 integrates into the genome
by target primed reverse transcription (TPRT) using the free
30-OH at the endonuclease cut site on the genomic DNA as a
primer and the L1 RNA as template (20) (Figure 1A).
In this study, we describe a novel system utilizing L1 retro-
transposition for stable siRNA expression and gene silencing
in human cells. This system was demonstrated to signiﬁcantly
reduce both exogenous and endogenous gene expression and
may have potential applications in molecular therapeutics.
MATERIALS AND METHODS
Cell culture
HeLa cells were grown in high glucose (4.5 g/l) DMEM sup-
plemented with 10% fetal bovine serum, 2 mM L-glutamine,
100 U/ml penicillin and 0.1 mg/ml streptomycin (all from
Invitrogen, Carlsbad, CA) in a humidiﬁed 5% CO2 incubator
at 37 C.
Plasmid constructs
Oligonucleotide primer sequences used in this study are avail-
able upon request. The neo-cassette tagged L1RP was inserted
into pBluescript II KS( ) phagemid vector (Stratagene,
La Jolla, CA) to create pBSKS-L1RP-neo. DNA oligonuc-
leotides encoding control shRNA sequence, 50-ACTACCG-
TTGTTATAGGTG-30, which expresses an siRNA with
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doi:10.1093/nar/gni056limited homology to any known sequences in the human,
mouse and rat genomes (Ambion, Austin, TX), green ﬂuor-
escence protein (GFP) target sequence, 50-GGCTACGTC-
CAGGAGCGCA-30 (21), and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) target sequence, 50-GTGGATAT-
TGTTGCCATCA-30 (Ambion), were synthesized by Integ-
rated DNA Technologies (Coralville, IA). The complementary
oligonucleotides were annealed and inserted downstream of
the H1 promoter into ApaI–EcoRI linearized pSilencer3.0-H1
vector (Ambion) according to the manufacturer’s instructions.
The RNAi-cassettes composed of H1 promoter and shRNA
sequence were ampliﬁed by PCR using Expand High Fidelity
PCR System (Roche, Mannheim, Germany) and inserted just
downstream of the neo-cassette in pBSKS-L1RP-neo to create
pL1-Silencer constructs.
GFP expression plasmid pCEP-puro-GFP was constructed
by insertion of the EGFP gene from pEGFP-N1 vector
(Clontech, Palo Alto, CA) downstream of the cytomegalovirus
(CMV) promoter in pCEP-puro, which is derived from pCEP4
vector (Invitrogen) except that the hygromycin resistance gene
intheoriginalvectorwasreplacedwithapuromycinresistance
gene. Inserted sequences in all constructs were veriﬁed by
DNA sequencing.
Cell culture and transfection
To establish L1-mediated stable RNAi cell lines, HeLa cells
were seeded in six-well dishes at 3 · 10
5 cells/well and grown
to 60% conﬂuence before transfection. Each transfection
received 1 mg plasmid DNA, 3 ml FuGENE 6 transfection
reagent (Roche) and 2 ml complete medium according to
the manufacturer’s protocol. Antibiotic selection with G418
(400 mg/ml; Invitrogen) was started 48 h post-transfection.
Untransfected cells were used to determine when antibiotic
selection had been completed. After G418 application for
24 h, 10% of cells from each well were removed to a l00 mm
Figure 1. L1 retrotransposon-based RNAi system. (A) Mechanism of L1 retrotransposition. (B) Strategy for L1-based RNAi. A selectable neo-cassette for
retrotransposition is inserted in the 30-UTR of L1RP, followed by an RNAi-cassette composed of the H1 promoter, the 19 bp sense and antisense sequences of
aspecificgeneseparatedbya9bploopsequenceandapolIIIterminatorofsixthymidines.Abbreviations:pA,polyadenylationsignal;NEO,neogene;SD,splicing
donor site; and SA, splicing acceptor site. Arrows indicate transcription start sites. (C) Structure of L1-based RNAi vector (pL1-Silencer) and expressed shRNA.
(D) L1-based RNAi system. Transfection of pL1-Silencer into cultured cells is followed by the transcription of L1-RNAi sequence, its integration into the host
genome and stable siRNA expression.
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single colonies appeared. In  1 week, several individual col-
onies were picked from each 100 mm dish and grown separ-
ately in one-well of a six-well dish. When nearly conﬂuent,
cells were transferred onto 75 mm
2 ﬂasks for future analysis.
Genomic DNA extraction and PCR
Genomic DNA was extracted using QIAamp Blood kit
(Qiagen, Valencia, CA) and 100 ng of genomic DNA was
used for PCR by using PCR Core kit (Roche). A forward
primer located within the neo sequence upstream of the
g-globin intron and a reverse primer located within the H1
promoter were designed so that a 775 bp PCR product would
be produced if the intron had been correctly spliced out in
contrast to a 1679 bp product with an intact intron. An aliquot
of 100 ng of genomic DNA was used in each 50 ml PCR
performed by using PCR Core kit with an initial denaturation
step at 94 C for 2 min, followed by 42 cycles of 94 C for 15 s,
61 C for 30 s, 72 C for 2 min and a ﬁnal extension at 72 C
for 10 min. The 2 min extension time also allowed for the
ampliﬁcation of unspliced sequence. A positive control for
unspliced product using 10 ng pBSKS-L1RP-neo plasmid as
template was performed in parallel. An aliquot of 5 ml of PCR
product was electrophoresed and puriﬁed with QIAquick
PCR Puriﬁcation kit (Qiagen) for sequencing.
Real-time PCR and RT–PCR
An aliquot of 1 mg of total RNA isolated with RNeasy RNA
Isolation kit (Qiagen) and treated with DNase I (Invitrogen)
was used for cDNA synthesis with random hexamer and
SuperScript First-Strand Synthesis System (Invitrogen). Real-
time ampliﬁcation was performed on the ABI Prism 7700
Sequence Detection System (Applied Biosystems, Foster
City, CA) using Sybergreen PCR Core Reagent kit (Applied
Biosystems) with reverse transcribed cDNA or Taqman PCR
Core Reagents (Applied Biosystems) with genomic DNA.
Real-time RT–PCR of b-actin and GAPDH was performed
as control. Standard calibration curves were constructed and
the relative expression of each sample was calculated as
described previously (22). Each sample was analyzed twice
and each real-time RT–PCR experiment contained two non-
template control wells. PCR productswere conﬁrmed as single
bands on gel electrophoresis.
Northern-blot analysis
Probe for siRNA detection was composed of 19 nt siRNA
sequence in either sense or antisense direction, synthesized
and 50-digoxigenin labeled by Integrated DNA Technologies.
RNA highly enriched for small RNA species (no larger than
200 nt) was extracted from wild-type and knockdown HeLa
cell lines using mirVana miRNA Isolation kit (Ambion)
following the manufacturer’s protocol. Only 1.5 mg of each
sample and 0.1 ng of probe was loaded on a 15% TBE-Urea
gel (Invitrogen) and electrophoresed at 180 V for 1.5 h. The
gel was stained in 1· TBE plus 1 mg/ml ethidium bromide
for 40 min and photographed before electroblotting onto
positively charged nylon membrane (Roche) in a Trans-
Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad,
Hercules, CA) at 20 V for 1.5 h. The membrane was hybrid-
ized with 100 ng/ml probe at 37 C overnight. On the following
day, the membrane was washed twice in 2· SSC at room
temperature (21 C) for 5 min each and twice in 0.1· SSC
at 37 C for 15 min each. Digoxigenin signals were detected
with DIG Northern Starter kit (Roche) following the manufac-
turer’s instructions.
Western-blot analysis
Total protein from stable HeLa RNAi cell lines was extracted
with M-PER mammalian protein extraction reagent (Pierce,
Rorkford, IL). Of the total protein, 7.5 mg was electrophoresed
in a 10% SDS–PAGE gel, transferred onto a PVDF membrane
(Millipore, Billerica, MA) in a Trans-Blot SD Semi-Dry Elec-
trophoreticTransferCell(Bio-Rad)at15Vfor30min,blocked
for2hatroomtemperaturewith5%skimmilkinTris-buffered
salinecontaining0.05%Tween-20(TTBS)andincubatedover-
night with primary polyclonal anti-GFP antibody (Clontech)
diluted 1:400, monoclonal anti-GAPDH antibody (Chemicon,
Temecula, CA) diluted 1:200 or monoclonal anti-b-actin anti-
body (Sigma-Aldrich, St Louis, MO) diluted 1:20 000. The
membrane was then probed with secondary peroxidase-
conjugated anti-mouse or anti-rabbit antibodies (1:5000 dilu-
tion in TTBS; Amersham Biosciences, Piscataway, NJ) for 1 h
and developed with an ECL1 Detection kit (Amersham
Biosciences) according to the manufacturer’s instructions.
Fluorescence-activated cell scanning
Established RNAi cell lines targeting GFP were transfected
with 1 mg of pCEP-puro-GFP for each well of six-well dish.
Puromycin selection was started 48 h post-transfection. On
day 5, cells were analyzed by using ﬂuorescence-activated
cell scanning (FACS) as described previously (23).
Immunofluorescence
Cells were ﬁxed with ice-cold acetone for 10 min, then
blocked in 10% normal goat serum, incubated in primary
mouse anti-human GAPDH antibody (1:100; Chemicon)
and rabbit anti-human cytokerin antibody (1:500; DAKO,
Carpinteria, CA), and visualized using species appropriate
secondary IgG conjugated with ﬂuorescein isothiocyanate
or Texas Red (Vector, Burlingame, CA) diluted 1:40 in
phosphate-buffered saline. DAPI (Vector) counterstaining
for nuclear DNA was performed.
Retrotransposition assay
Retrotransposition assay was performed on days 3, 4, 5, 6, 7, 8,
9 and 10 post-transfection as described previously (23,24).
Statistical analysis
Data analysis was performed using the SPSS statistics soft-
ware package. All the results were expressed as means – SE,
and P < 0.05 was used for signiﬁcance.
RESULTS
Development of an L1-based RNAi system
To obtain stable siRNA expression in vivo, we combined
pol III promoter driven shRNA production with L1-
mediated integration. An active human L1, L1RP (25), was
tagged in its 30-UTR with an antisense neo-cassette driven by a
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signal (Figure 1B). The neo gene was disrupted by a g-globin
intron in the same direction as L1 such that neo could only
be expressed following L1 retrotransposition (26). An RNAi-
cassette containing H1 promoter and speciﬁc shRNA target-
ing sequence wasthen inserted downstream ofthe neo-cassette
tagged L1 to create the L1-RNAi vector, pL1-Silencer
(Figure 1B and C). After transfection of such a vector into
wild-type HeLa cells, individual clones in which tagged L1
had retrotransposed were selected by G418. Most importantly,
since the RNAi-cassette is located downstream of the neo-
cassette, the TPRT mechanism during retrotransposition
essentially guarantees that G418 resistant clones will also inte-
grate the RNAi-cassette into the host genome (Figure 1D).
This strategy provides an easy and efﬁcient method for stable
siRNA expression in vivo.
Specific inhibition of exogenous and endogenous
gene expression
To test the efﬁcacy of our system, stable knockdown cell lines
were ﬁrst established by transfecting wild-type HeLa with
the pL1-Silencer containing either control or GFP-targeted
shRNA sequence. The established cell lines were then
transfected with plasmid pCEP-puro-GFP such that cells
expressing GFP would be selected by puromycin. By real-time
RT–PCR, we found that the mRNA level of exogenous GFP
was reduced by 50–60% (P < 0.001), in all the four lines that
were analyzed, compared with controls (Figure 2A). Consist-
ently, GFP expression was also markedly inhibited in knock-
down lines as revealed by western-blot analysis (Figure 2B)
and its ﬂuorescence was reduced by up to 87% after FACS
analysis (P < 0.001, Figure 2C and D). Using our system, the
expression of an endogenous gene, GAPDH, was also signi-
ﬁcantly reduced at both mRNA and protein levels (P < 0.001,
Figure 3). It is noteworthy that all the stable knockdown cell
lines had been cultured for over 3 months before analysis was
performed to ensure that the episomal plasmid had been lost.
In addition, the silencing of targeted genes was observed over
multiple generations. Finally, northern-blot analysis was per-
formed to demonstrate successful siRNA expression in stable
knockdown cells. We detected speciﬁc siRNA expression in
allGAPDHandGFPknockdowncelllinesbutnotinwild-type
HeLa (Figure 4 for GAPDH and data not shown for GFP).
Furthermore, the siRNA expression level correlated inversely
with the GAPDH expression observed in each line (Figure 4),
providing a possible explanation for the different levels of
silencing observed among them.
Knockdown clones are derived from
L1 retrotransposition
To conﬁrm that the stable silencing was derived from
the retrotransposed RNAi-cassette but not integrated
Figure 2. Inhibition of exogenous GFP expression using L1-based RNAi system. (A) Real-time RT–PCR results of GFP mRNA expression in stable HeLa lines
expressing control or GFP-targeted siRNA (n = 6). (B) Western-blot analysis of GFP expression in control or knockdown clones. (C) Typical FACS dot plots of
GFP expression in control and knockdown clones. (D) Normalized GFP fluorescence in control and knockdown clones by FACS (n = 4).
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using genomic DNA extracted from G418 resistant clones and
a pair of primers ﬂanking the g-globin intron that disrupts the
neo gene (Figure 5A). As expected, the intron was correctly
spliced out in all stable knockdown clones (Figure 5B), i.e. a
retrotransposition event had occurred. Although permitted by
the PCR condition, no unspliced product was detected, indic-
ating the absence of the integrated pL1-Silencer plasmid in the
host genome. We also performed PCR with a reverse primer
further downstream and conﬁrmed by sequencing that the
intact RNAi-cassette had been integrated into the genomes
of the knockdown clones (data not shown).
Characterization of L1 retrotransposition in
human cells
Since our RNAi system is based on L1 retrotransposition, we
further characterized its properties in human cells, using a
GFP-cassette to replace the neo-cassette for retrotransposition
detection (24). Consistent with a previous report (24), we
found that retrotransposition was not detectable until 2–3
days post-transfection and the percentage of cells hosting a
retrotransposition event increased in a linear manner up to
day 7 (Figure 6A). We also found that retrotransposition
indeed reached a plateau around day 7 and few new events
occurred after that (Figure 6B).
We then used a real-time PCR strategy to estimate the
number of retrotransposition events per cell (Figure 6C). A
pair of primers was designed within the GFP gene ﬂanking the
g-globin intron and a bridging Taqman probe was designed
such that no ﬂuorescence would be emitted unless the intron
Figure 4. Northern-blot analysis of siRNA expression in GAPDH knockdown
cells. Upper panel (from left to right): lane 1, 19 nt probe containing the sense
strandsequenceofGAPDHsiRNAasamolecularweightmarker(MW),which
wasalsousedastheprobetodetectantisensesiRNAinthetestsamples;lane2:
wild-typeHeLa(wt);lanes3–6:fourGAPDHknockdownlines(#1,2,3and4).
Position of antisense siRNA is indicated. Note the inverse relationship of
siRNA expression seen here with GAPDH mRNA and protein expression
(Figure 3A and B). Lower panel: gel post-electrophoresis. Positions of 5.8S,
5S and tRNAs are indicated.
Figure 3. InhibitionofendogenousGAPDHexpressionusingL1-basedRNAisystem.(A)Real-timeRT–PCRresultsofGAPDHmRNAexpressioninstableHeLa
linesexpressingcontrol,GFP-targetedorGAPDH-targetedsiRNA(n=6).(B)Western-blotanalysisofGAPDHproteinexpressionincontrolorGAPDHknockdown
clones. (C) Immunofluorescent staining of GAPDH (green) and cytokeratin (red) in control and knockdown cells. Nucleus is counterstained with DAPI (blue).
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experiment, we examined retrotransposition of the GFP-
cassette tagged L1 in HeLa cells by both FACS and
real-time PCR. FACS analysis revealed that on day 7 post-
transfection 3.4% of transfected cells hosted retrotransposition
event(s) from a tagged L1RP, whereas  21.3 copies of GFP
sequence resulting from retrotransposition were detected per
1000 GAPDH gene copies (i.e. 500 HeLa cells) or 4.3 GFP
copies per 100 cells (Figure 6D). Thus, on average 1.25 (4.3/
3.4)retrotransposition events of tagged L1RP occurred percell.
A similar result was obtained with tagged L1.3. Therefore,
most transfected cells host no more than one retrotransposition
event from a tagged L1, meaning that most knockdown clones
contain only one RNAi-cassette in their genome.
DISCUSSION
Current siRNA production methods include both in vitro and
in vivo strategies. In vitro chemically or enzymatically gen-
erated siRNA is limited, costly and produces only a transient
effect; in addition, special cautions have to be taken when
handling and working with RNA. All these reasons limit
the application in whole animal models or clinical therapy
(2,27). A more practical strategy is to produce siRNA
in vivo from an expression cassette. The most popular delivery
vectors used are plasmid- and retrovirus-based, because they
are efﬁcient and capable of conferring stable RNAi. However,
inclusion of plasmid sequence into the host genome and
insertional mutation caused by retroviral integration (28)
are always a concern, especially when clinical therapy is
contemplated (2).
L1 retrotransposon has long been proposed as a novel
molecular delivery tool. However, because reverse transcrip-
tion during retrotransposition infrequently produces products
>3 kb in length (29,30), its delivery capacity is limited. In this
study, we avoided this problem by delivering a short siRNA
expression cassette of  150 bp. Our L1-based RNAi system
allowed successful siRNA expression (Figure 4) and stable
reduction of both exogenous and endogenous gene expression
(Figures 2 and 3) and thus provides a simple and efﬁcient
method for stable gene silencing in vivo. Actually, the GFP
silencing induced by our system (up to 87%, Figure 2) was
greater than that induced by chemically synthesized siRNA of
the same sequence ( 64%) (21). Although GAPDH reduction
was not as dramatic as that of GFP, we probably approached
its limit since GAPDH is a critical gene involved in cellular
metabolism and greater reduction may lead to cell death.
Indeed, we observed that GAPDH knockdown clones were
smaller and grew slower (data not shown). Most importantly,
using the same H1 promoter and shRNA sequence against
GAPDH our system delivered silencing similar to that of
the pSilencer3.0-H1 plasmid (Ambion) and much greater
silencing than that of the pSIREN-derived retroviral deliv-
ery system (Clontech) (data not shown).
In summary, our L1-mediated RNAi system has unique
advantages over current delivery vehicles: (i) L1 proteins
have no immunogenicity even upon inadvertent expression
from heterologous promoters in the genome. (ii) Unlike ret-
roviral integration that always includes an LTR with strong
promoter activity,L1 usuallyloses its internal promoter during
integration and is thus unable to activate host genes. (iii) A
single copy of the integrated RNAi-cassette is sufﬁcient to
elicit strong silencing, which is consistent with the previous
reports (31). Therefore, in comparison with the multiple
integrations of retrovirus and their preference for active
genes (32) and the tandem repeat insertions of plasmid, the
random and single integration of L1 retrotransposon is espe-
ciallybeneﬁcialbecauseitreducesthe likelihoodofinsertional
mutations and non-speciﬁc interferon response owing to the
overexpression of siRNA from multiple transgenes (2,27).
(iv) All the G418 resistant clones tested were positive for
silencing, suggesting that the integrated RNAi-cassette prob-
ably resided in an active chromatin structure owing to its
proximity to the expressed neo gene. Interestingly, we also
observed an inverse correlation between siRNA expression
and gene silencing (Figure 4) in GAPDH knockdown clones.
Variation in GAPDH siRNA expression among different
clones was probably owing to position effect at the different
genomic integration sites. Also, all the knockdown clones
contained a retrotransposed RNAi-cassette but not an integ-
rated pL1-Silencer plasmid (Figure 5B). Taken together, our
system is more efﬁcient at producing stable knockdown clones
compared with plasmid vector delivery. (v) No expertise in
viral handling is required; and compared with a recently
reported transposon-based RNAi delivery method (33), our
system avoids co-transfection of two plasmids. In conclusion,
Figure 5. G418 resistant clones are derived from retrotransposition. (A) PCR
strategy to characterize retrotransposition of tagged L1. The primer pair
(F and R) produces a PCR product of 1679 bp before or of 775 bp post
retrotransposition of tagged L1. (B) Electrophoresis of the PCR product of
genomic DNA from knockdown clones, plus controls with no DNA
( DNA),wild-typeHeLaDNA (Mock)orpL1-Silencerplasmid(PlusIntron).
MW, molecular weight marker. Arrows indicate the positions of expectant
bands.
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stable gene silencing in mammalian cells; and more import-
antly, it may represent a highly attractive tool for molecular
therapy. For example, L1 retrotransposition probably occurs in
human lymphoid cells (23,34); therefore, ex vivo therapy tar-
geting host factors involved in HIV life cycle, e.g. TSG101
and AIP1 (35), or pathogenic oncoproteins associated with
lymphoid malignancies, e.g. TEL-AML1 and E2A-HLF
(36), can be contemplated.
This is among the ﬁrst studies using L1 retrotransposon for
transgene delivery. The system certainly has limitations at
this infant stage. For example, delivery of the plasmid-
based construct into certain cells can be difﬁcult. However,
this problem may be alleviated with the improvement of pre-
sent methods (e.g. electroporation and liposome carrier). Also,
L1 retrotransposition may have cell type restrictions (37).
This may be overcome by the modiﬁcation of L1 50-UTR,
e.g. inclusion of a heterologous promoter to get L1 transcripts
in other cell types (38), since transcription is proposed as the
rate-limiting step of retrotransposition (15,23). One could also
create synthetic L1 with novel properties (39). In conclusion,
our L1-based RNAi system can provide efﬁcient stable gene
silencing in human cells and has promising practical applica-
tions in molecular therapeutics.
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FACS (n = 4). JM111, a negative control of L1 with eliminated retrotransposition activity. (B) Retrotransposition frequency reaches a plateau around day 7 post-
transfection (n = 4). (C) Real-time PCR strategy to characterize retrotransposition of GFP-cassette tagged L1. Arrows, primers; bar, Taqman probe. (D) Retro-
transpositionfrequencyofexogenouslyintroducedL1RP,L1.3andJM111inHeLaonday7post-transfectionasrevealedinparallelbyreal-timePCR(upperpanel)in
whichdataarerepresentedascopynumbersofintactGFPper1000GAPDHandbyFACS(lowerpanel)inwhichdataarerepresentedaspercentageofGFPpositive
cells among transfected cells.
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